Table 2.
Incident dyslipidemia by antiretroviral therapy use, HIV patients, Vitoria, Brazil (n = 498).
| Variables | Dyslipidemiaa n (%) |
No dyslipidemia n (%) |
p-Value |
|---|---|---|---|
| Zidovudine | |||
| No | 50 (45.0) | 187 (48.3) | 0.590 |
| Yes | 61 (55.0) | 200 (51.7) | |
| Lamivudine | |||
| No | 3 (2.7) | 3 (0.8) | 0.128 |
| Yes | 108 (97.3) | 384 (99.2) | |
| Tenofovir | |||
| No | 62 (55.9) | 198 (51.2) | 0.383 |
| Yes | 49 (44.1) | 189 (48.8) | |
| Nevirapine | |||
| No | 104 (93.7) | 349 (90.2) | 0.255 |
| Yes | 7 (6.3) | 38 (9.8) | |
| Efavirenz | |||
| No | 81 (73.0) | 236 (61.0) | 0.021 |
| Yes | 30 (27.0) | 151 (39.0) | |
| Lopinavir/r | |||
| No | 59 (53.2) | 261 (67.4) | 0.006 |
| Yes | 52 (46.8) | 126 (32.6) | |
| Atazanavir/r | |||
| No | 92 (82.9) | 331 (85.5) | 0.492 |
| Yes | 19 (17.1) | 56 (14.5) | |
| Fosamprenavir/r | |||
| No | 108 (97.3) | 382 (98.7) | 0.297 |
| Yes | 3 (2.7) | 5 (1.3) | |
a
Dyslipidemia: total cholesterol above 200 and HDL bellow 40 for men and 50 for women.